Intersect nabs $30M for drug/device combo

Intersect ENT nailed down $30 million in new Series D funding that attracted major investor interest from Medtronic ($MDT) and a number of other high-profile players. Executives aren't wasting any time, and they are using the cash infusion to rapidly accelerate commercial expansion plans for the company's quarter-sized implants to treat chronic sinusitis. Story

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.